Key result
Impaired LV GLS plus elevated native T1 linked to ~7.2-fold higher post-AMI MACE risk.
Why the study?
Does combining left ventricular global longitudinal strain (LV GLS) and native T1 mapping on non-contrast cardiac MRI improve prognostic risk stratification for major adverse cardiac events compared to conventional contrast-enhanced CMR markers and clinical risk scores in patients with acute myocardial infarction undergoing PCI?
Cohort (n=1,253)
Observers who analyzed CMR images and the physician who recorded clinical endpoints were blinded to patient outcomes and CMR data, respectively
Yes
Does combining left ventricular global longitudinal strain (LV GLS) and native T1 mapping on non-contrast cardiac MRI improve prognostic risk stratification for major adverse cardiac events compared to conventional contrast-enhanced CMR markers and clinical risk scores in patients with acute myocardial infarction undergoing PCI?
Combining non-contrast cardiac MRI parameters (native T1 mapping and LV global longitudinal strain) provides superior MACE risk stratification after acute myocardial infarction compared to conventional contrast-enhanced CMR models and established clinical risk scores.
May support non-contrast CMR for post-AMI MACE stratification; leaves open prospective validation versus contrast-enhanced markers.
Background Left ventricular global longitudinal strain (LV GLS) and native T1 mapping are prognostic markers after acute myocardial infarction (AMI), but the prognostic value of their combined assessment beyond established risk stratification remains uncertain. Objective To evaluate the incremental prognostic value of combining LV GLS and native T1 mapping for major adverse cardiac events (MACE) after AMI and to assess their potential for non-contrast risk stratification. Methods AMI patients undergoing percutaneous coronary intervention (PCI) and cardiac MRI (CMR) from four centers between February 2017 and September 2024 were retrospectively enrolled. Major adverse cardiac events (MACEs) were defined as all-cause death, life-threatening arrhythmias, cardiac death, reinfarction and heart failure hospitalization. Cox regression and Kaplan-Meier analyses were used to assess the incremental prognostic value of LV strain and native T1 mapping. Results A total of 1253 participants (development cohort, n = 1002; external validation cohort, n = 251) were included in the study. Over a median follow-up of 43 months, 137 and 36 participants experienced MACE in the development and external validation cohort. In the development cohort, the non-contrast Model 3 incorporating clinical variables, LVEF, native T1 z score and LV GLS improved discrimination over Model 2 incorporating conventional contrast-enhanced CMR markers (LGE, MVO and IMH) (C-index, 0.780 vs. 0.736; P = 0.033). Native T1 and LV GLS showed better prognostic performance than the GRACE and Glasgow CMR Risk Scores. The findings were validated in the external validation cohort. Conclusion Combined native T1 mapping and LV GLS provided complementary prognostic information, improved risk stratification and reclassification beyond established risk factors, and supported the potential of a contrast-free CMR strategy that outperformed a conventional contrast-enhanced model.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) conducted a cohort in Acute myocardial infarction (AMI) (n=1,253). Impaired LV global longitudinal strain (LV GLS >= -11%) and elevated native T1 mapping (z score >= 2.1) on non-contrast CMR vs. Minimal risk group (LV GLS < -11% and native T1 z score < 2.1) and conventional contrast-enhanced CMR markers (LGE, MVO, IMH) was evaluated on Major adverse cardiac events (MACE: composite of all-cause death, life-threatening arrhythmias, cardiac death, reinfarction, and heart failure hospitalization) (Adjusted HR 7.158 (High-risk group: LV GLS >= -11% and native T1 z score >= 2.1 vs. minimal risk); Model 3 vs Model 2 C-index 0.780 vs 0.736, 95% CI 3.208-14.660, p=<0.001). Combined impaired LV GLS and elevated native T1 mapping identified high-risk AMI patients (adjusted HR 7.158) and outperformed contrast-enhanced CMR for MACE discrimination (C-index 0.780 vs 0.736).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: